EDX Medical Group and Caris Life Sciences enter a three-year distribution deal for AI-driven cancer diagnosis in the UK and Nordic countries.

EDX Medical Group has entered a three-year distribution agreement with Caris Life Sciences to distribute advanced molecular profiling services in the UK and Nordic countries. This collaboration aims to enhance personalized cancer treatment through AI-driven diagnostics that assess DNA, RNA, and proteins. The agreement enables EDX to provide these services to clinicians, improving treatment decision-making and patient outcomes in cancer care.

September 02, 2024
5 Articles